{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:47:39Z","timestamp":1789253259064,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T00:00:00Z","timestamp":1739059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016285","name":"TDR","doi-asserted-by":"publisher","award":["2021\/1188581-0"],"award-info":[{"award-number":["2021\/1188581-0"]}],"id":[{"id":"10.13039\/100016285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aims to evaluate the effectiveness, safety, and impact on health-related quality of life (HQoL) of a fully oral shortened regimen for Rifampicin-Resistant\/Multidrug-Resistant Tuberculosis (RR\/MDR-TB) over 9 to 12 months under programmatic conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted on an all-oral modified Shortened Treatment Regimen (mSTR) comprising linezolid (Lzd), bedaquiline (Bdq), levofloxacin (Lfx), clofazimine (Cfz), and cycloserine (Cs). Patients with RR\/MDR-TB were enrolled between January and December 2022 across seven drug-resistant TB units in the Dominican Republic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 113 patients were enrolled, with 87% achieving culture conversion at two months. Treatment outcomes revealed that 79% of patients were successfully treated and didn\u2019t relapse six months after the end of the treatment, 14% were lost to follow-up during the treatment, 6% deceased, and one experienced treatment failure due to Adverse Drug Reactions (ADRs). Adverse events of Special interest (AESI) were common, with 82% of patients experiencing at least one AE with high proportion of QT interval prolongation, elevated transaminases, and anemia. A total of 12% of the patients experiencing Serious Adverse Events (SAEs). Improvement in HQoL dimensions was noted throughout treatment, with the EQ-VAS score increasing by an average of 15.5 by treatment end.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The high treatment success rate of the 5-drug mSTR facilitated the adaptation and integration of a shortened treatment regimen lasting 9 to 12 months in routine care in Dominican Republic. SAEs were -rare. Although AESI were frequent, they were manageable in most cases. Continuous monitoring, particularly with regard to the use of Lzd and Bdq, is crucial to effectively mitigating risks. Since September 2023, this short all oral treatment regimen is the recommended approach for patients with RR\/MDR-TB in the Dominican Republic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-024-10417-w","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T14:13:07Z","timestamp":1739110387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of a modified short all oral treatment regimen for rifampicin-multidrug resistant tuberculosis in Dominican Republic"],"prefix":"10.1186","volume":"25","author":[{"given":"Mar\u00eda","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamile Celis","family":"Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanea","family":"Encarnaci\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"De los Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissette","family":"Portorreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seydou Benjam\u00edn","family":"Sombie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimata Bintou","family":"Sall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne Simone","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,9]]},"reference":[{"key":"10417_CR1","unstructured":"Pan American Health Organization. Tuberculosis [Internet]. Pan American Health Organization. 2022 [cited 2023 Dec 23]. Available from: https:\/\/www.paho.org\/en\/topics\/tuberculosis"},{"issue":"3","key":"10417_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.22206\/cysa.2022.v6i3.pp95-103","volume":"6","author":"RE Melgen","year":"2022","unstructured":"Melgen RE. Impacto De La Pandemia COVID-19 en El control De La Tuberculosis en Rep\u00fablica Dominicana. Ciencia Y Salud. 2022;6(3):95\u2013103.","journal-title":"Ciencia Y Salud"},{"key":"10417_CR3","unstructured":"World Health Organization. Global tuberculosis report 2023 [Internet]. Geneva; 2023 [cited 2023 Dec 22]. Available from: https:\/\/iris.who.int\/"},{"issue":"6","key":"10417_CR4","first-page":"490","volume":"2","author":"MA Espinal","year":"1998","unstructured":"Espinal MA, B\u00e1ez J, Soriano G, Garcia V, Laszlo A, Reingold AL, et al. Drug-resistant tuberculosis in the Dominican Republic: results of a nationwide survey. Int J Tuberc Lung Dis. 1998;2(6):490\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"10417_CR5","unstructured":"Organizaci\u00f3n Panamericana de la Salud. Tuberculosis en las Am\u00e9ricas. Informe regional 2021 [Internet]. Washington. 2022. Available from: https:\/\/iris.paho.org\/bitstream\/handle\/10665.2\/57084\/9789275326497_spa.pdf?sequence=11&isAllowed=y"},{"key":"10417_CR6","doi-asserted-by":"crossref","unstructured":"Rodriguez M, Monedero I, Caminero JA, Encarnaci\u00f3n M, Dominguez Y, Acosta I et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis [Internet]. 2013 Apr 1 [cited 2023 Dec 22];17(4):520\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23485386\/","DOI":"10.5588\/ijtld.12.0481"},{"key":"10417_CR7","unstructured":"Ministerio de Salud P\u00fablica y Asistencia Social. Informe de gesti\u00f3n del programa de tuberculosis Rep\u00fablica Dominicana, 2020 [Internet]. Santo Domingo. 2020. Available from: https:\/\/repositorio.msp.gob.do\/handle\/123456789\/2071"},{"key":"10417_CR8","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: Treatment Drug-resistant tuberculosis treatment [Internet]. Geneva. 2020 [cited 2023 Dec 23]. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/332397\/9789240007048-eng.pdf?sequence=1"},{"key":"10417_CR9","unstructured":"World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision [Internet]. Washington. 2020. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/79199\/9789241505345_eng.pdf?sequence=1"},{"key":"10417_CR10","unstructured":"World Health Organization. Global Tuberculosis report 2022 [Internet]. Geneva. 2022. Available from: http:\/\/apps.who.int\/bookorders"},{"key":"10417_CR11","unstructured":"World Health Organization. The ShORRT initiative on tuberculosis research in the Region of the Americas [Internet]. 2022 [cited 2023 Dec 23]. Available from: https:\/\/tdr.who.int\/newsroom\/news\/item\/25-05-2022-the-shorrt-initiative-on-tuberculosis-research-in-the-region-of-the-americas"},{"key":"10417_CR12","unstructured":"World Health Organization. Module 4: Treatment WHO operational handbook on tuberculosis Drug-resistant tuberculosis treatment 2022 update [Internet]. 2022 [cited 2024 Jan 14]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240065116"},{"key":"10417_CR13","unstructured":"EQ-5D-5L. | EuroQol [Internet]. [cited 2024 Mar 31]. Available from: https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-5l\/"},{"issue":"2","key":"10417_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"key":"10417_CR15","unstructured":"World health organization. ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package Protocol [Internet]. 2020 [cited 2024 Jan 28]. Available from: https:\/\/tdr.who.int\/docs\/librariesprovider10\/shorrt-initiative\/shorrt-generic-protocol-june2020_en.pdf?sfvrsn=df85f6c1_3"},{"key":"10417_CR16","unstructured":"Active tuberculosis drug-safety monitoring. and management (aDSM): framework for implementation [Internet]. [cited 2024 Jan 28]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-TB-2015.28"},{"key":"10417_CR17","unstructured":"World Health Organization. Active tuberculosis drug-safety monitoring and management (aDSM). Framework for implementation [Internet]. Geneva. 2015. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/204465\/WHO_HTM_TB_2015.28_eng.pdf?sequence=1"},{"key":"10417_CR18","unstructured":"National Institutes of Allergy and Infectious Diseases, National Institutes of Health. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. 2017."},{"key":"10417_CR19","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]. 2017. Available from: https:\/\/www.meddra.org\/"},{"key":"10417_CR20","doi-asserted-by":"publisher","unstructured":"Devlin N, Parkin D, Janssen B. Methods for Analysing and Reporting EQ-5D Data [Internet]. Springer; 2020. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK565678\/https:\/\/doi.org\/10.1007\/978-3-030-47622-9","DOI":"10.1007\/978-3-030-47622-9"},{"key":"10417_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijid.2022.11.007","volume":"126","author":"TMP Nguyen","year":"2023","unstructured":"Nguyen TMP, Le THM, Merle CSC, Pedrazzoli D, Nguyen NL, Decroo T, et al. Effectiveness and safety of bedaquiline-based, modified all-oral 9\u201311-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam. Int J Infect Dis. 2023;126:148\u201354.","journal-title":"Int J Infect Dis"},{"issue":"91","key":"10417_CR22","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.3855\/jidc.13757","volume":"15","author":"E Zhdanova","year":"2021","unstructured":"Zhdanova E, Goncharova O, Davtyan H, Alaverdyan S, Sargsyan A, Harries AD, et al. 9\u201312 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan. J Infect Dev Ctries. 2021;15(91):S66\u201374.","journal-title":"J Infect Dev Ctries"},{"key":"10417_CR23","doi-asserted-by":"crossref","unstructured":"Trubnikov A, Hovhannesyan A, Akopyan K, Ciobanu A, Sadirova D, Kalandarova L et al. Effectiveness and safety of a shorter treatment regimen in a setting with a high burden of multidrug-resistant tuberculosis. Int J Environ Res Public Health. 2021;18(8).","DOI":"10.3390\/ijerph18084121"},{"key":"10417_CR24","doi-asserted-by":"crossref","unstructured":"Jeyakumar SM, Bhui NK, Singla N, Vilvamani S, Mariappan MV, Padmapriyadarsini C et al. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary Tuberculosis. Ther Drug Monit [Internet]. 2023 Dec 1 [cited 2024 Aug 5];45(6):754\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37296501\/","DOI":"10.1097\/FTD.0000000000001111"},{"key":"10417_CR25","unstructured":"The end TB. STraTegy global strategy and targets for tuberculosis prevention, care and control after 2015 a. 2014."},{"key":"10417_CR26","doi-asserted-by":"publisher","first-page":"100444","DOI":"10.1016\/j.jctube.2024.100444","volume":"36","author":"NF Maranchick","year":"2024","unstructured":"Maranchick NF, Peloquin CA. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2024;36:100444.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10417_CR27","doi-asserted-by":"crossref","unstructured":"Lecai J, Mijiti P, Chuangyue H, Qian G, Weiguo T, Jihong C. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study. Front Public Health. 2023;11.","DOI":"10.3389\/fpubh.2023.1134938"},{"key":"10417_CR28","doi-asserted-by":"crossref","unstructured":"Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J [Internet]. 2019 Dec 1 [cited 2024 Mar 1];54(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31601711\/","DOI":"10.1183\/13993003.01522-2019"},{"key":"10417_CR29","doi-asserted-by":"crossref","unstructured":"Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med [Internet]. 2020 Apr 1 [cited 2024 Aug 6];8(4):383\u201394. Available from: http:\/\/www.thelancet.com\/article\/S2213260020300473\/fulltext","DOI":"10.1016\/S2213-2600(20)30047-3"},{"key":"10417_CR30","doi-asserted-by":"crossref","unstructured":"Huerga H, Khan U, Bastard M, Mitnick CD, Lachenal N, Khan PY et al. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis [Internet]. 2022 Oct 15 [cited 2024 Aug 6];75(8):1307\u201314. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35243494\/","DOI":"10.1093\/cid\/ciac176"},{"key":"10417_CR31","doi-asserted-by":"crossref","unstructured":"Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-\/XDR-tuberculosis: available evidence and future scenarios. European Respiratory Journal. Volume 45. European Respiratory Society; 2015. pp. 25\u20139.","DOI":"10.1183\/09031936.00145014"},{"key":"10417_CR32","doi-asserted-by":"crossref","unstructured":"Mase A, Lowenthal P, True L, Henry L, Barry P, Flood J. Low-dose linezolid for treatment of patients with Multidrug-resistant tuberculosis. Open Forum Infect Dis. 2022;9(12).","DOI":"10.1093\/ofid\/ofac500"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10417-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10417-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10417-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T05:24:29Z","timestamp":1739165069000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10417-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10417"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10417-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4271608\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,9]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study obtained ethical approval from the WHO Research Ethics Review Board (Generic Protocol ID: ERC0003305, 08\/06\/2020) and the Ethics Committee of the Dr. Hugo Mendoza National Center for Research in Maternal and Child Health. Informed consent was obtained from each participant or respondent. For participants under the age of 16, consent to participate was obtained from their parents or legal guardians. All methods adhered to relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors and respondents involved in this research have consented to the publication of all paper details, data, tables, and images. These materials will be freely accessible on the internet.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The findings and conclusions of this article are the intellectual responsibility of its authors and do not necessarily represent the official position of Special Programme for Research and Training in Tropical Diseases of World health Organization, the Pan American Health Organization, Nacional Health Service, and Ministry of Public Health of Dominican Republic.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"196"}}